Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

The fatal disease caused by Bacillus anthracis is preventable with a prophylactic vaccine. The currently available anthrax vaccine requires a lengthy immunization schedule, and simpler and more immunogenic options for protection against anthrax are a priority for development. In this report we descr...

Full description

Bibliographic Details
Main Authors: Bruce K Brown, Josephine Cox, Anita Gillis, Thomas C VanCott, Mary Marovich, Mark Milazzo, Tanya Santelli Antonille, Lindsay Wieczorek, Kelly T McKee, Karen Metcalfe, Raburn M Mallory, Deborah Birx, Victoria R Polonis, Merlin L Robb
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-11-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2974626?pdf=render

Internet

http://europepmc.org/articles/PMC2974626?pdf=render

Similar Items